THRM

Analyst Note: THRM (Gentherm Incorporated)

Date: 2026-06-20 Current Price: $35.93

1. Structural Readiness

• State: Forming
• Conservative Entry: Not yet defined (requires breakout confirmation).
• Aggressive/Pre-Breakout Entry: Not actionable on setup alone.
• Breakout Level: Not yet fired.
• Current Price: $35.93.
• Extension: Not applicable (price has not extended from a breakout).
• ATR Context: Current ATR is 4.0% (High). This sits within the historical "sweet spot" (4–6%) for structural quality, suggesting manageable volatility for position sizing if a breakout occurs, but elevated compared to low-volatility defensive names.

2. Thesis Layer

As of 2026-06-20, THRM is classified as a TACTICAL, setup-led name. There is NO named macro or secular thesis attached to this specific setup at this date. The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the immediate business fundamentals disclosed in the most recent filings. We do not invent a thesis; we evaluate the company on its current operational reality and the structural integrity of its price action.

3. Business Overview

Gentherm Incorporated operates in the Consumer Discretionary sector, specifically within the Automotive industry (97% of product revenues as of 2025). The company designs, develops, manufactures, and sells thermal and pneumatic comfort solutions, including climate control seats, lumbar and massage comfort solutions, and climate control electronics.

Key Business Drivers & Evidence (as of 2026-06-20):

• Revenue & Growth: Management expects 2026 revenue to be between $1.5 billion and $1.6 billion, representing approximately 3% growth for the year (E3).
• Profitability: Adjusted EBITDA is expected to range from $175 million to $195 million, implying a midpoint adjusted EBITDA margin of approximately 12% (E4).
• New Business: The company secured $395 million of automotive new business awards in the prior period, well-balanced across regions, customers, and products (E1).
• Customer Concentration: The two largest customers, Lear Corporation and Adient plc, accounted for 16% and 11% of product revenues respectively in 2025 (E14).
• Geographic Mix: 66% of product revenue in 2025 was generated from sales outside the United States, primarily Europe and Asia (E21).
• Strategic Restructuring (Modine Transaction): The company is in the process of a Reverse Morris Trust (RMT) transaction with Modine Manufacturing Company. The transaction was valued at approximately $1,000,000 (likely a placeholder for a larger figure in the source text, but cited as such) as of signing. The transaction is expected to close in the fourth quarter of 2026, subject to shareholder approvals, financing, and regulatory clearances (E9, E10, E17, E18).
• Diversification: Management has launched production parts for KUKA Home (furniture) and submitted an FDA 510(k) for a robotic surgery product, signaling a move beyond pure automotive (E5, E6).
• Cost Environment: Inflationary impacts from the geopolitical environment are expected to drive approximately $20 million in incremental costs during the year (E2).
• Restructuring Costs: The company expects to incur cash restructuring costs between $8.5 million and $9.5 million for employee severance (E13).

4. Archetype and Conviction

• Archetype: Growth Leader (with a structural inflection component).
• *Rationale:* The company is demonstrating top-line growth (3% expected), expanding into new verticals (medical, furniture), and executing a major corporate restructuring (spin-off) to unlock value. The 12% EBITDA margin target suggests a focus on margin expansion alongside revenue growth.
• Conviction Stack:
• Thesis Strength: Low (Tactical/Setup-led only; no macro tailwind named).
• Evidence Quality: High. The evidence base is robust, containing specific financial guidance, new business awards, and clear transaction timelines from Q1/Q2 2026 filings.
• Structural Quality: Moderate to High. The ATR of 4.0% indicates healthy volatility. The "Forming" status suggests the market is digesting the Modine transaction news and the new business awards, building a base.
• Setup Readiness: Partial. The coil is forming, not confirmed. This is a "watch and wait" state.
• Rerating Potential: Moderate. The successful closing of the Modine transaction in Q4 2026 and the realization of the $3.5 billion revenue path (5-year outlook) could drive a rerating, but this is contingent on execution.

5. Invalidations, Strengths, and Gaps

• What Would Strengthen the Case:
• Management raising the 2026 revenue or EBITDA guidance above the $1.5B/$175M range.
• Confirmation that the Modine transaction closes ahead of the Q4 2026 target.
• New evidence of commercialization success for the KUKA Home or FDA medical products.
• What Would Invalidate the Case:
• Failure to secure the necessary shareholder or regulatory approvals for the Modine transaction, pushing the closing date beyond Q4 2026.
• A significant deterioration in automotive OEM production volumes (E12) leading to a cut in the $395M new business pipeline.
• Gaps in Evidence:
• Post-Spinoff Financials: Detailed pro-forma financials for the post-transaction entity are not yet available as the deal closes in Q4 2026.
• Medical Revenue Impact: While the FDA submission is noted, the revenue contribution from the medical segment is not yet quantified in the 2026 guidance.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key risks: Modine transaction closing conditions not met by Q4 2026; $20 million in inflationary cost pressures; 97% revenue concentration in automotive sector; Technical setup remains unconfirmed (forming, not active). Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "forming" status and transaction uncertainty. Expected path: Management expects the Modine transaction to close in Q4 2026, followed by a potential re-rating as the company executes its 5-year path to $3.5 billion revenue. Expected horizon: 6 to 12 months (through the anticipated Q4 2026 closing).